Technical Analysis for GMAB - Genmab A/S

Grade Last Price % Change Price Change
F 22.57 -2.38% -0.55
GMAB closed down 2.38 percent on Wednesday, October 30, 2024, on approximately normal volume.
Earnings due: Nov 6
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Gapped Down Weakness 0.00%
Bollinger Band Squeeze Range Contraction -2.38%
Bollinger Band Squeeze Range Contraction -2.46%
BB Squeeze Started Range Contraction -2.46%
Inside Day Range Contraction -2.46%
Up 3 Days in a Row Strength -2.46%
Pocket Pivot Bullish Swing Setup -2.38%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 14 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Down 2 % about 15 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Gapped Down (Full) about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genmab A/S Description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Long-Term Care Facilities
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Drugs Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Genetics Acute Myeloid Leukemia Immunotherapies Lymphoma Parkinson's Disease Non Small Cell Lung Cancer Multiple Sclerosis Multiple Myeloma Orphan Drug Breakthrough Therapy Amyloid Amyloidosis Antibody Drug Conjugate Chronic Lymphocytic Leukemia Lymphocytic Leukemia Advanced Cancer Camidanlumab Tesirine Cd20 Copenhagen Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Genmab

Is GMAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.89
52 Week Low 22.39
Average Volume 831,675
200-Day Moving Average 27.41
50-Day Moving Average 25.06
20-Day Moving Average 23.16
10-Day Moving Average 22.90
Average True Range 0.40
RSI (14) 31.51
ADX 45.43
+DI 13.63
-DI 32.60
Chandelier Exit (Long, 3 ATRs) 23.10
Chandelier Exit (Short, 3 ATRs) 23.60
Upper Bollinger Bands 23.89
Lower Bollinger Band 22.43
Percent B (%b) 0.1
BandWidth 6.33
MACD Line -0.57
MACD Signal Line -0.68
MACD Histogram 0.1001
Fundamentals Value
Market Cap 14.74 Billion
Num Shares 653 Million
EPS 0.94
Price-to-Earnings (P/E) Ratio 24.01
Price-to-Sales 1.07
Price-to-Book 4.04
PEG Ratio 1.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.97
Resistance 3 (R3) 23.01 22.91 22.90
Resistance 2 (R2) 22.91 22.81 22.89 22.88
Resistance 1 (R1) 22.74 22.75 22.70 22.70 22.86
Pivot Point 22.65 22.65 22.63 22.63 22.65
Support 1 (S1) 22.48 22.55 22.43 22.44 22.28
Support 2 (S2) 22.38 22.48 22.36 22.26
Support 3 (S3) 22.21 22.38 22.24
Support 4 (S4) 22.17